Photo by MAXSHOT.PL from Shutterstock.com
GlaxoSmithKline (GSK) is a multinational pharmaceutical and biotechnology company. As a global supplier of medicines and vaccines for influenza, malaria, COVID-19, and other infectious diseases, GSK has serviced different governments around the world. Here’s a list of top GlaxoSmithKline government contracts.
Table of Contents
1. BARDA and DoD Finalized an Agreement for Advanced Development of the COVID-19 Vaccines
Photo by Viacheslav Lopatin from Shutterstock.com
- Contracting activity: Biomedical Advanced Research and Development Authority and Department of Defense
- Value: $2 billion
- Contract date: July 31, 2020
GlaxoSmithKline and Sanofi secured an agreement with the Biomedical Advanced Research and Development Authority, and collaborated with the Department of Defense, to develop the COVID-19 investigational adjuvanted vaccine. The agreement covered work for clinical trials and large-scale manufacturing of 100 million doses.
Under the $2 billion contract, the companies were tasked with manufacturing demonstration project while the clinical trials were ongoing. The adjuvanted vaccine doses were a part of the COVID-19 vaccination campaign of the U.S. government’s Operation Warp Speed. It aimed to deliver millions of doses by the end of 2020.
The U.S. government purchase also included the ability to acquire up to 500 million additional doses and support for fill-finish manufacturing for ready packaging and shipment as soon as the clinical trial was proven successful or the Food and Drug Administration (FDA) was to authorize its use.
2. GSK and Vir Biotechnology Secured a Contract for the Purchase of Sotrovimab
Photo by ice_blue from Shutterstock.com
- Contracting activity: U.S. government purchase
- Value: $1 billion
- Contract date: November 17, 2021
The U.S. government awarded GSK and Vir Biotechnology contracts amounting to $1 billion to purchase Sotrovimab, an investigational monoclonal antibody. FDA granted Emergency Use Authorization (EUA) in May 2021 for early treatment of COVID-19. The contract aimed to expand nationwide access to Sotrovimab to reach more Americans.
Under the binding agreements, the company was tasked to supply the initial order of Sotrovimab by December 17, 2021, and additional doses for purchase options by March 2022. Funding came from the BARDA, part of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
On top of the U.S. government purchase contracts, GSK also secured a Joint Procurement Agreement with the European Commission. Overall, the company was projected to supply a total number of 750,000 doses globally.
3. HHS Awarded a Follow on Contract for the Procurement of Sotrovimab Therapeutic Treatment
Photo by Cryptographer from Shutterstock.com
- Contracting activity: Department of Health and Human Services
- Contract type: Modification to the previously awarded firm-fixed-price contract
- Value: $945 million
- Contract date: January 10, 2022
GlaxoSmithKline was awarded a contract modification for the procurement of 340,048 additional doses with the option to procure another 715,680 doses of Sotrovimab therapeutic treatment. The contract delivery was scheduled for June 30, 2022, with expected completion by September 30, 2022.
Work commenced in Durham, North Carolina, with the total funding amount of $945 million from the American Rescue Plan Act of 2021 obligated at the time of the award. The Department of Health and Human Services served as the contracting activity for the procurement efforts.
The contract modification was a follow-on award to improve access to Sotrovimab among Americans. On November 15, 2021, GlaxoSmithKline secured a $651 million contract for the procurement of Sotrovimab, with estimated completion on March 31, 2022.
4. ACC Finalized an Award for Procurement Activities of COVID-19 Vaccines in the U.S.
Photo by hedgehog94 from Shutterstock.com
- Contracting activity: Army Contracting Command
- Contract type: Firm-fixed-price contract
- Value: $342 million
- Contract date: January 30, 2020
The U.S. Army Contracting Command awarded GlaxoSmithKline a $342 million contract to procure and distribute COVID-19 vaccines. The contract was finalized to support Armed Forces personnel primarily throughout the United States and other military locations worldwide.
Work performance commenced in Research Triangle Park, North Carolina, and was estimated for completion by February 28, 2021. Funding was finalized from the fiscal 2020 research, development, test, and evaluation (Army) funds, with the total contract amount of $342 million awarded at the time of the award.
5. ACC Signed a Contract with GSK for Storage and Distribution Efforts of Sotrovimab
Photo by Cryptographer from Shutterstock.com
- Contracting activity: Army Contracting Command
- Contract type: Firm-fixed-price contract
- Value: $280 million
- Contract date: September 29, 2021
GlaxoSmithKline secured a contract award for the storage and distribution of Sotrovimab. Work commenced in Durham, North Carolina, with an estimated contract completion by May 19, 2022. The U.S. Army Contracting Command served as the contracting activity with a funding obligation to the total contract value of $280 million at the time of the award.
The FDA granted the pharmaceutical giant’s Sotrovimab EUA as an investigational single-dose intravenous infusion. It’s a treatment for mild-to-moderate COVID-19 in people at least 12 years old or 40 kgs. The medicine is proven to prevent the progression to hospitalization or death of high-risk patients with COVID-19-positive test results.
Frequently Asked Questions
What is GlaxoSmithKline?
Photo from GlaxoSmithKline Official Website
GlaxoSmithKline, also known as GSK, is one of the largest pharmaceutical companies in the world. The company manufactures essential medicines, such as Blenrep & Zejula for oncology, Apretude for HIV, and Sotrovimab for COVID-19. GSK has generated $12 billion as of 2021 across its commercial, R&D, manufacturing, and corporate functions.
Leading GSK in its global operations is Dame Emma Walmsley, who has served as the Chief Executive Officer since April 2017. The pharmaceutical company has a diverse talent pool, with 21.7% of senior leaders in the U.S. from different ethnicities. As of 2022, GSK ranks 294th in the Global 500 companies list by Fortune.
Where is GSK located in the U.S.?
GlaxoSmithKline has large-scale operations across the United States. The company employs more than 3,000 employees with flexible and hybrid workspaces to develop and innovate medicines, vaccines, and other pharmaceutical products.
Here’s the list of GSK locations based on their functions.
- Research & Development Function operates eight smart labs across Upper Providence, Pennsylvania; Boston, Massachusetts; San Francisco, California; and Rockville, Maryland.
- Manufacturing Function develops medicines for diseases such as myeloma, asthma, lupus, and HIV in various U.S. sites, including Rockville, Maryland; Upper Merion, Pennsylvania; Hamilton, Montana; and Zebulon, North Carolina.
- Commercial Function has offices in Durham, North Carolina, and Philadelphia, Pennsylvania, handling the company’s corporate business and development.
Is GSK a U.S. company?
GSK traces its roots to Plough Court Pharmacy in London, England, in 1715. The company had the vision to get ahead of diseases and positively impact an individual’s health. While the company has since expanded worldwide, including the U.S., GSK still has its global headquarters in London, United Kingdom.
GlaxoSmithKline: “Ahead Together”
Photo by Golden Shrimp from Shutterstock.com
GSK government contracts have greatly improved healthcare worldwide. The company’s range of products and solutions have been crucial in solving health crises, including the COVID-19 pandemic, influenza outbreaks, and more.
